Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? (Q37549027)

21 August 2017

1 reference

title

Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? (English)

1 reference

systemic lupus erythematosus

21 August 2017

0 references

author name string

Mariana J Kaplan

series ordinal

1

1 reference

21 August 2017

17 June 2009

1 reference

21 August 2017

Translational Research

1 reference

21 August 2017

154

1 reference

21 August 2017

61-69

1 reference

21 August 2017

2

1 reference

Etiopathogenesis of systemic lupus erythematosus

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Pathogenesis of lupus nephritis: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Epidemiology of cardiovascular disease in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Accelerated atherogenesis in autoimmune rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Systemic nature of endothelial dysfunction in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Systemic lupus erythematosus predicts increased left ventricular mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Premature coronary-artery atherosclerosis in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Inflammation in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Cardiovascular involvement in systemic autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Insights into atherosclerosis therapy in antiphospholipid syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Flow-mediated arterial dilation in primary antiphospholipid syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Vascular manifestations of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Chylomicron metabolism is markedly altered in systemic lupus erythematosus

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Peripheral vascular endothelial dysfunction and apoptosis in old monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Endothelial cell apoptosis in angiogenesis and vessel regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Current perspective on the role of apoptosis in atherothrombotic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Circulating endothelial progenitor cells, vascular function, and cardiovascular risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Circulating endothelial progenitor cells and cardiovascular outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Circulating endothelial cells and vascular injury in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Circulating endothelial cells in vascular disorders: new insights into an old concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Interferon-alpha in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Microarray analysis of gene expression in lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Immune Interferon in the Circulation of Patients with Autoimmune Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Type I interferon correlates with serological and clinical manifestations of SLE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Type I interferon in systemic lupus erythematosus and other autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Review: Milstein Award lecture: interferons and cancer: where from here?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Type I interferon: potential therapeutic target for psoriasis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Precocious intima-media thickening in patients with primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Simvastatin improves endothelial function in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Recognition of single-stranded RNA viruses by Toll-like receptor 7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Mycophenolate mofetil and atherosclerosis: results of animal and human studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Is atherosclerosis a complication of long-term corticosteroid treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.05.005

10.1016/J.TRSL.2009.05.005

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19595437